Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 5.05
CERS's Cash to Debt is ranked higher than
69% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: 42.14 vs. CERS: 5.05 )
CERS' s 10-Year Cash to Debt Range
Min: 0.62   Max: 14206.57
Current: 5.05

0.62
14206.57
Equity to Asset 0.58
CERS's Equity to Asset is ranked higher than
67% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. CERS: 0.58 )
CERS' s 10-Year Equity to Asset Range
Min: 0.06   Max: 0.9
Current: 0.58

0.06
0.9
F-Score: 3
Z-Score: -4.45
M-Score: -3.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -71.36
CERS's Operating margin (%) is ranked higher than
72% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. CERS: -71.36 )
CERS' s 10-Year Operating margin (%) Range
Min: -2168.13   Max: -7.75
Current: -71.36

-2168.13
-7.75
Net-margin (%) -109.28
CERS's Net-margin (%) is ranked higher than
68% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. CERS: -109.28 )
CERS' s 10-Year Net-margin (%) Range
Min: -1946.68   Max: 53.6
Current: -109.28

-1946.68
53.6
ROE (%) -101.27
CERS's ROE (%) is ranked higher than
56% of the 829 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. CERS: -101.27 )
CERS' s 10-Year ROE (%) Range
Min: -2276.92   Max: 37.03
Current: -101.27

-2276.92
37.03
ROA (%) -51.97
CERS's ROA (%) is ranked higher than
60% of the 904 Companies
in the Global Biotechnology industry.

( Industry Median: -17.94 vs. CERS: -51.97 )
CERS' s 10-Year ROA (%) Range
Min: -141.63   Max: 22.27
Current: -51.97

-141.63
22.27
ROC (Joel Greenblatt) (%) -1292.78
CERS's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 881 Companies
in the Global Biotechnology industry.

( Industry Median: -200.53 vs. CERS: -1292.78 )
CERS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4385.29   Max: -144.38
Current: -1292.78

-4385.29
-144.38
Revenue Growth (%) 1.20
CERS's Revenue Growth (%) is ranked higher than
77% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. CERS: 1.20 )
CERS' s 10-Year Revenue Growth (%) Range
Min: -44.7   Max: 52.9
Current: 1.2

-44.7
52.9
EBITDA Growth (%) 17.70
CERS's EBITDA Growth (%) is ranked higher than
91% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. CERS: 17.70 )
CERS' s 10-Year EBITDA Growth (%) Range
Min: -52.9   Max: 123.5
Current: 17.7

-52.9
123.5
EPS Growth (%) 15.10
CERS's EPS Growth (%) is ranked higher than
90% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: -12.20 vs. CERS: 15.10 )
CERS' s 10-Year EPS Growth (%) Range
Min: -30.1   Max: 21
Current: 15.1

-30.1
21
» CERS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CERS Guru Trades in Q3 2013

Jim Simons Sold Out
Chuck Royce 4,031,511 sh (-1.47%)
» More
Q4 2013

CERS Guru Trades in Q4 2013

Chuck Royce 3,860,211 sh (-4.25%)
» More
Q1 2014

CERS Guru Trades in Q1 2014

Chuck Royce 3,807,005 sh (-1.38%)
» More
Q2 2014

CERS Guru Trades in Q2 2014

Chuck Royce 3,725,505 sh (-2.14%)
» More
» Details

Insider Trades

Latest Guru Trades with CERS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.20
CERS's P/B is ranked higher than
61% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 6.10 vs. CERS: 6.20 )
CERS' s 10-Year P/B Range
Min: 0.82   Max: 55
Current: 6.2

0.82
55
P/S 7.50
CERS's P/S is ranked higher than
77% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 19.49 vs. CERS: 7.50 )
CERS' s 10-Year P/S Range
Min: 1.24   Max: 15.91
Current: 7.5

1.24
15.91
EV-to-EBIT -6.25
CERS's EV-to-EBIT is ranked higher than
66% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CERS: -6.25 )
CERS' s 10-Year EV-to-EBIT Range
Min: 33.1   Max: 61
Current: -6.25

33.1
61
Current Ratio 3.24
CERS's Current Ratio is ranked higher than
68% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.29 vs. CERS: 3.24 )
CERS' s 10-Year Current Ratio Range
Min: 1.03   Max: 9.96
Current: 3.24

1.03
9.96
Quick Ratio 2.62
CERS's Quick Ratio is ranked higher than
66% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 3.87 vs. CERS: 2.62 )
CERS' s 10-Year Quick Ratio Range
Min: 1.03   Max: 9.96
Current: 2.62

1.03
9.96

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.80
CERS's Price/Net Cash is ranked higher than
83% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 965.00 vs. CERS: 15.80 )
CERS' s 10-Year Price/Net Cash Range
Min: 1.88   Max: 103.13
Current: 15.8

1.88
103.13
Price/Net Current Asset Value 10.20
CERS's Price/Net Current Asset Value is ranked higher than
85% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 217.00 vs. CERS: 10.20 )
CERS' s 10-Year Price/Net Current Asset Value Range
Min: 1.73   Max: 68
Current: 10.2

1.73
68
Price/Tangible Book 6.60
CERS's Price/Tangible Book is ranked higher than
77% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 9.20 vs. CERS: 6.60 )
CERS' s 10-Year Price/Tangible Book Range
Min: 0.92   Max: 300
Current: 6.6

0.92
300
Price/Median PS Value 1.30
CERS's Price/Median PS Value is ranked higher than
77% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 1.94 vs. CERS: 1.30 )
CERS' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 92.9
Current: 1.3

0.24
92.9
Earnings Yield (Greenblatt) 76.50
CERS's Earnings Yield (Greenblatt) is ranked higher than
87% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. CERS: 76.50 )
CERS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 80.9
Current: 76.5

1.6
80.9
Forward Rate of Return (Yacktman) -18.33
CERS's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: -9.52 vs. CERS: -18.33 )
CERS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -83.5   Max: -72.5
Current: -18.33

-83.5
-72.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CU2.Germany
Cerus Corporation was incorporated in California in 1991 and reincorporated in Delaware in 1996. It is a biomedical products company which focuses on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The Company has worldwide rights for its INTERCEPT Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received CE marks and are being marketed and sold in a number of countries in Europe, The Commonwealth of Independent States, or CIS, the Middle East and selected countries in other regions around the world. The Company sells both the platelet and plasma systems using its direct sales force and through distributors. In addition, the Company is developing and plan to perform the required clinical trials for its INTERCEPT Blood System for red blood cells, or red blood cell system, for approval in Europe. The Company and its products are comprehensively regulated in the United States by the FDA and, in some instances, by state and local governments, and by comparable governmental authorities in other countries.
» More Articles for CERS

Headlines

Articles On GuruFocus.com
hummm royce adding Oct 05 2011 
Cerus Corp. Reports Operating Results (10-K) Mar 16 2011 
Cerus Corp. Reports Operating Results (10-Q) Aug 16 2010 
Cerus Corp. Reports Operating Results (10-Q) May 12 2010 
Cerus Corp. Reports Operating Results (10-Q) Nov 06 2009 
Cerus Corporation Announces Second Quarter Financial Results Jul 30 2009 
Cerus Corporation Extends Manufacturing Agreement with Fenwal Dec 15 2008 

More From Other Websites
Cerus to Present at the Baird 2014 Health Care Conference on September 3, 2014 Aug 28 2014
CERUS CORP Financials Aug 15 2014
CERUS CORP Files SEC form 10-Q, Quarterly Report Aug 08 2014
Cerus to Present at the Wedbush 2014 Life Sciences Management Access Conference on August 12, 2014 Aug 07 2014
CERUS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 31 2014
4:08 pm Cerus misses by $0.02, beats on revs; reaffirms FY14 revs guidance Jul 31 2014
Cerus Corporation Reports Second Quarter 2014 Results Jul 31 2014
Cerus to Release Second Quarter 2014 Results on July 31, 2014 Jul 17 2014
Cerus Submits Final Module in Premarket Approval (PMA) Application Process for INTERCEPT Platelets Jul 17 2014
CERUS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Jul 03 2014
CERUS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 16 2014
Cerus signs five-year agreement for INTERCEPT Blood System for platelets May 29 2014
Cerus Signs Five-Year Agreement With Belgian Red Cross Flanders for the INTERCEPT Blood System for... May 29 2014
CERUS CORP Files SEC form 10-Q, Quarterly Report May 12 2014
CERUS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 01 2014
Cerus Corporation Reports First Quarter 2014 Results May 01 2014
Cerus Announces Collaboration Agreement With Nipro for Innovative INTERCEPT Red Blood Cell System... Apr 29 2014
Cerus Announces Collaboration Agreement With Nipro for Innovative INTERCEPT Red Blood Cell System... Apr 29 2014
Cerus to Release First Quarter 2014 Results on May 1, 2014 Apr 21 2014
Cerus submits Medical Device license application for INTERCEPT plasma Apr 07 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK